Latest Pharma and Biotech News
Pharmaceutical
9 January 2025 Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to redefine the future of healthcare.
Today's issue
Refine Search
Pharmaceutical
Artbio, a radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), has named Margaret Yu its chief medical officer (CMO). 10 January 2025
Pharmaceutical
Chinese metabolic diseases specialist Hangzhou Sciwind Biosciences has announced details of a deal with Verdiva Bio for the global development and commercialization of a portfolio of therapies in territories outside of China and South Korea. 10 January 2025
Pharmaceutical
USA-based Light Horse Therapeutics has been established as a new small molecule therapeutics developer, with a $62 million Series A financing led by founding investor Versant Ventures and partnered with Novartis to identify and develop potentially advanced therapeutics. 10 January 2025
Pharmaceutical
The glaucoma market across the seven major markets is forecast to increase at a compound annual growth rate (CAGR) of 2.1% from $2.1 billion in 2023 to $2.5 billion in 2033. 10 January 2025
Pharmaceutical
German pharma major Bayer today announced top-line results of the Phase III study OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy in women with hormone receptor positive breast cancer or in women at high risk of developing breast cancer. 9 January 2025
Pharmaceutical
Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to redefine the future of healthcare. 9 January 2025
Pharmaceutical
UK headquartered Verdiva Bio Limited today announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. 9 January 2025
Pharmaceutical
Italy-based Newron Pharmaceuticals (SIX: NWRN, XETRA: NP5), a biopharma developing therapies for diseases of the central and peripheral nervous system, has announced a deal with South Korea’s Myung In Pharm. 9 January 2025
Pharmaceutical
British pharma major AstraZeneca has received positive news from the reimbursement from the UK’s health technology assessor. 9 January 2025
Pharmaceutical
German family-owned pain focused drugmaker Grünenthal announced today that Prof Dr Uli Brödl will assume the role of chief scientific officer (CSO) and a member of the corporate executive board, effective February 1, 2025. 9 January 2025
Pharmaceutical
Insilico Medicine, a biotechnology firm specializing in artificial intelligence-powered drug discovery, has raised over $100 million in a series E funding round. 8 January 2025
Pharmaceutical
Calico Life Sciences, a biotech founded by Alphabet and Arthur Levinson focused on the biology of aging and age-related diseases, has announced a setback. 8 January 2025
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Pharmaceutical
Antag Therapeutics, a Denmark-based biopharma developing novel treatments for obesity, has announced the appointment of Joerg Moeller as chief executive officer, effective immediately. 8 January 2025
Pharmaceutical
The US Food and Drug Administration has imposed a label change for two new respiratory syncytial virus (RSV) vaccine rivals. 8 January 2025
Pharmaceutical
Metsera today announced positive data from a 12-week Phase IIa clinical trial of MET-097i, its potential once-monthly, ultra-long acting, subcutaneously injectable, fully-biased, GLP-1 receptor agonist (RA). 7 January 2025
Pharmaceutical
Central nervous system (CNS) specialist Neuraxpharm Group has acquired Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of excessive daytime sleepiness (EDS) in adults with narcolepsy. 7 January 2025
Pharmaceutical
Japan-based FUSO Pharmaceutical Industries and Australia’s Dimerix Limited have entered into an exclusive development and license agreement for the development and commercialization of Dimerix’ Phase III drug candidate DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in Japan. 7 January 2025
Pharmaceutical
The heart failure market is projected to grow at a compound annual growth rate of 9.6% over the next decade, increasing from $13.5 billion in 2022 to $33.7 billion in 2032 across seven major markets, according to a report from analytics firm GlobalData. 7 January 2025
Pharmaceutical
A late-stage trial failure has dented Denali Therapeutics stock, with an announcement Monday revealing the HEALEY ALS study missed all endpoints. 7 January 2025
All news
Pharmaceutical
The National Institute for Health and Care Excellence (NICE) has published Final Guidance on a new medicine for the treatment of the most common inherited heart condition in England and Wales. 6 September 2023
Pharmaceutical
The UK is an attractive place to conduct life science research and development (R&D). However, we must caveat this statement with the words, ‘for now’. 6 September 2023
Pharmaceutical
Cambridge, US-based Apollo Therapeutics today announces the close of $226.5 million in a Series C financing led by lead investor Patient Square Capital. 6 September 2023
Pharmaceutical
US pharma company Tonix Pharmaceuticals Holding Corp lost nearly 9% of its stock market value on Tuesday. 6 September 2023
Pharmaceutical
Marie-France Tschudin, president, innovative medicines international and chief commercial officer of Novartis, has decided to leave the Swiss pharma giant and will step down from the executive committee of Novartis. 6 September 2023
Pharmaceutical
Dr Monica Shaw has joined the commercial leadership team of US pharma major Bristol Myers Squibb’s as senior vice president, major markets. 6 September 2023
Pharmaceutical
Egypt is set to join BRICS next year as the bloc expands to include six new members. 6 September 2023
Pharmaceutical
The Russian segment of drug public procurements significantly declined this year, mainly as a result of a significant drop of purchases under various state programs, The Pharma Letter’s local correspondent reports. 6 September 2023
Pharmaceutical
Shares of Spanish dermatology-focused drugmaker Almirall rallied yesterday, after the company revealed in a brief stock exchange filing that it is looking to expand its therapeutic range. 5 September 2023
Pharmaceutical
Palforzia was going to be the keystone product in Nestle’s strategic expansion into biotech, but the Swiss food and drink giant has finally thrown in the towel. 5 September 2023
Pharmaceutical
Italy’s privately-held drug developer Italfarmaco Group today revealed that its Marketing Authorization Application (MAA) for Givinostat as a potential treatment for Duchenne muscular dystrophy (DMD) has been submitted to the European Medicine Agency. 5 September 2023
Pharmaceutical
Dutch specialty pharma firm Pleco Therapeutics has appointed Dr Henno Welgemoed in the newly created role of chief medical officer (CMO). 5 September 2023
Pharmaceutical
A sizeable sum in excess of $7.75 billion was spent across pharmaceutical M&A in August. 4 September 2023
Pharmaceutical
Privately-held Italian drugmaker Angelini Pharma today shared positive findings from post-hoc analyses of the C017 open-label extension (OLE) study. 4 September 2023
Pharmaceutical
Shares of Australian specialty pharma firm Mayne Pharma Group closed up 9.2% at A$3.68 today, after it released full-year fiscal 2023 financials, showing that reported revenues were A$183.6 million (US$118.5 million), up 17% on FY 2022. 4 September 2023
Pharmaceutical
AbbVie has announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorization for Aquipta (atogepant) for the prophylaxis of migraine in adults who have at least four migraine days per month. 4 September 2023
Pharmaceutical
Since first demonstrating clinical success in the treatment of obesity, Wegovy (semaglutide) has garnered ever increasing amounts of interest from patients, providers and investors alike. 4 September 2023
Pharmaceutical
Mid-sized French drugmaker Ipsen today revealed the appointment of Christelle Huguet as executive vice president, head of research and development. 4 September 2023
Pharmaceutical
The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) recommends new measures to avoid exposure of children to topiramate-containing medicines in the womb, because the medicine may increase the risk of neurodevelopmental problems after exposure during pregnancy. 4 September 2023
Pharmaceutical
Germany has some strengths to show in the competition among locations for pharmaceutical R&D, but has nevertheless been falling behind internationally for some years, for example in the area of clinical trials, according to a posting on the web site of the German pharma trade group the vfa. 4 September 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze